317806-90-9

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-Morpholinoethoxy)naphthalen-1-amine is used as a building block in the synthesis of various pharmaceuticals due to its potential applications in medicinal chemistry and drug development.
Used in Dye Industry:
4-(2-Morpholinoethoxy)naphthalen-1-amine is used as a precursor in the production of dyes, leveraging its chemical properties to create a range of colorants for different applications.
Used in Materials Science:
4-(2-Morpholinoethoxy)naphthalen-1-amine is utilized in materials science for its versatile chemical properties, contributing to the development of new materials with specific characteristics.
Used in Polymer Synthesis:
It serves as a component in polymer synthesis, where its reactivity and structure are employed to create polymers with tailored properties for various industrial uses.

InChI:InChI=1/C16H20N2O2/c17-15-5-6-16(14-4-2-1-3-13(14)15)20-12-9-18-7-10-19-11-8-18/h1-6H,7-12,17H2

Upstream product

• 285984-35-2 [4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]carbamic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 
• 5959-56-8 4-amino-1-naphthol hydrochloride 
• 285984-22-7 tert-butyl 4-hydroxynaphthalen-1-ylcarbamate 
• 317806-88-5 4-nitro-1-(2-morpholinethoxy)naphthalene 
• 2834-90-4 4-amino-1-naphthol 

Downstream Products

• 285983-48-4 BIRB-796 
• 850312-03-7 1-(5-tert-butyl-2-(3-iodo-4-methylphenyl)-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]urea 
• 848144-64-9 2-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 
• 476010-09-0 1-[5-tert-butyl-2-(2-hydroxy-4-methyl-phenyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea 
• 874131-47-2 3-bromo-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-benzamide 
• 848148-18-5 2-(5-tert-butyl-2-m-tolyl-2H-pyrazol-3-yl)-N-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetamide 
• 489432-47-5 4-(3-tert-butyl-5-{3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-ureido}-pyrazol-1-yl)-benzoic acid 
• 611168-85-5 1-[2-(3-nitrophenyl)-5-tert-butyl-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea 

Relevant academic research and scientific papers

1,4-DISUBSTITUTED NAPHTALENES AS INHIBITORS OF P38 MAP KINASE

In general, the present invention relates to compounds capable of inhibiting P38, methods for inhibiting P38 in vivo or in vitro, diagnostics for determining activity in the treatment of P38 and/or cytokine-associated conditions and methods for treating c

Microwave-assisted synthesis of N-pyrazole ureas and the p38α inhibitor BIRB 796 for study into accelerated cell ageing

Microwave irradiation of substituted hydrazines and β-ketoesters gives 5-aminopyrazoles in excellent yield, which can be transformed to the corresponding N-carbonyl derivatives by treatment with an isocyanate or chloroformate. Derivatization of 4-nitronaphth-1-ol using predominantly microwave heating methods and reaction with an N-pyrazole carbamate provides a rapid route to the N-pyrazole urea BIRB 796 in high purity, as a potent and selective inhibitor of p38α mitogen-activated protein kinase for the study of accelerated ageing in Werner syndrome cells. The Royal Society of Chemistry 2006.

UREA DERIVATIVES AS KINASE MODULATORS

The invention provides methods and compositions for treating conditions mediated by various kinases wherein derivatives of urea compounds are employed. The invention also provides methods of using the compounds and/or compositions in the treatment of a variety of diseases and unwanted conditions in subjects.

1,4-Disubstituted benzo-fused compounds

Disclosed are novel 1,4-disubstituted benzo-fused compounds wherein G, X, L, Q, n and Y are defined herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic infla

1,4-Benzofused urea compounds useful in treating cytokine mediated diseases

Disclosed are 1,4-disubstituted benzo-fused urea compounds of formula (I): wherein Ar, X, A, L, and Q of formula(I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Compounds useful as anti-inflammatory agents

Disclosed are novel aromatic compounds of the formula (I) wherein G, X, Ar, L and Q are defined herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.

Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate

We report on a series of N-pyrazole, N′-aryl ureas and their mode of binding to p38 mitogen activated protein kinase. Importantly, a key binding domain that is distinct from the adenosine 5′-triphoshate (ATP) binding site is exposed when the conserved activation loop, consisting in part of Asp168-Phe169-Gly170, adopts a conformation permitting lipophilic and hydrogen bonding interactions between this class of inhibitors and the protein. We describe the correlation of the structure-activity relationships and crystallographic structures of these inhibitors with p38. In addition, we incorporated another binding pharmacophore that forms a hydrogen bond at the ATP binding site. This modification affords significant improvements in binding, cellular, and in vivo potencies resulting in the selection of 45 (BIRB 796) as a clinical candidate for the treatment of inflammatory diseases.